Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E) Meeting Abstract

  

Authors:	Basch, E. M.; Sholz, M. C.; de Bono, J. S.; Vogelzang, N. J.; De Souza, P. L.; Marx, G. M.; Vaishampayan, U. N.; George, S.; Schwarz, J. K.; Antonarakis, E. S.; O'Sullivan, J. M.; Kelabasty, A. R.; Chi, K. N.; Dreicer, R.; Hutson, T. E.; Mangeshkar, M.; Holland, J. S.; Weitzman, A.; Scher, H. I.
Abstract Title:	Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E)
Meeting Title:	2015 Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	7 Suppl.
Meeting Dates:	2015 Feb 26-28
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-03-01
Language:	English
ACCESSION:	WOS:000356886700143
PROVIDER:	wos
DOI:	10.1200/jco.2015.33.7_suppl.141
Notes:	Meeting Abstract: 141 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/77308